(603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 603538 · · 12 pages · Chinese
Summary by 6ix AI
The report confirms the accuracy and completeness of the financial information presented, with the board of directors assuming legal responsibility for its content. It includes significant financial data such as total revenue and net profit, along with comparisons to previous periods. The report also outlines the company's total assets and shareholders' equity as of the reporting date.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Ningbo Menovo Pharmaceutical Co., Ltd. on 6ix
Earlier from Ningbo Menovo Pharmaceutical
- (603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Announcement on Obtaining the European CEP Certificate for Pregabalin API
- (603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Announcement on Signing of Quadripartite Supervision Agreement Following the Change of Sponsor
- (603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate for Tofacitinib Citrate Sustained-release Tablets by Wholly-owned Subsidiary
- (603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Announcement on Acceptance by Shanghai Stock Exchange of Application for 2026 Private Placement of A-Shares
- Announcement on Change of Sponsor and Sponsor Representative
Later from Ningbo Menovo Pharmaceutical
All Ningbo Menovo Pharmaceutical news releasesFollow Ningbo Menovo Pharmaceutical into a list and get an email when it puts out news.
Follow Ningbo Menovo Pharmaceutical